SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A

SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A

SSSE:603718
2.82
CNY
-0.08
(-2.76%)
-0.46EPS
2.01BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.63
0.59
0.56
0.52
0.48
0.36
0.46
0.29
0.52
0.47
0.38
0.43
0.29
0.43
Basic EPS, GAAP
0.23
0.21
0.17
0.13
0.18
0.03
0.02
0.01
0.08
0.19
0.1
0.27
-0.48
-0.48
Free Cash Flow per Basic Share
0.24
0.05
0.11
-0.04
-0.08
-0.13
0.03
0.15
0.01
0.43
-0.03
0.06
0.07
- -
Dividend per Share
0.2
0.09
0.25
0.05
0.06
0.06
0.01
- -
- -
- -
0.06
0.03
0.19
0.11
Book Value per Share
1.01
1.13
1.43
1.52
1.66
1.64
1.65
1.64
1.56
1.77
1.85
2.37
1.35
1.39
Tangible Book Value per Share
0.93
1.05
1.33
1.32
1.48
1.12
1.13
1.13
1.06
1.31
1.45
0.76
0.69
0.45
Basic Weighted Avg Shares
506
485
561
658
632
710
608
893
673
640
629
634
649
645
Sales/Revenue/Turnover
319
285
317
343
304
255
278
259
347
300
241
271
188
277
Operating Margin (%)
40.12
34.53
30.82
18.39
30.91
1.7
-0.92
-8.35
10.71
22.15
2.09
10.89
25.06
20.75
Depreciation Expense
25
28
30
46
52
54
58
58
58
47
40
37
18
- -
Net Income, GAAP
119
101
95
86
114
21
12
9
54
122
63
171
-311
-310
Effective Tax Rate (%)
15.01
14.68
15.7
8.91
11.04
- -
486.83
- -
20.08
15.64
10.73
12.72
- -
- -
Profit Margin (%)
37.26
35.48
30.14
24.91
37.46
8.37
4.37
3.44
15.51
40.54
26.12
63.16
-165.77
-111.85
Working Capital
291
305
682
569
361
140
165
102
305
344
146
592
484
405
LT Debt
- -
- -
86
130
- -
- -
- -
- -
3
15
- -
14
10
83
Total Equity
501
559
963
1,005
1,075
1,025
993
962
987
1,111
1,175
1,703
896
983
Return on Invested Capital (%)
22.42
16.86
11.45
5.79
7.48
- -
-2.63
- -
4.69
5.44
4.12
10.38
- -
- -
Return on Capital (%)
24.22
18.39
12.38
9.4
11.55
- -
-1.89
- -
7.33
13.11
6.77
11.24
- -
- -
Return on Common Equity (%)
24.85
19.56
12.97
8.98
11.09
2
1.15
0.84
5.22
11.33
5.33
12.33
-25.5
-24.96

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
24
38
31
LT Borrowings
56
46
62
LT Finance Leases
11
21
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
652
652
649
Market Capitalization
3,018
1,728
2,005

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
591
601
572
Cash, Cash Equivalents & STI
388
345
290
Accounts Receivable, Net
118
126
146
Inventories
70
105
110
Total Current Liabilities
138
227
167
Payables & Accruals
- -
- -
- -
ST Debt
24
38
31
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.89%
3.69%
-47.39%
Free Cash Flow
451.07%
809.93%
22.53%
Net Income, GAAP
34.3%
94.24%
-281.93%
Sales/Revenue/Turnover
-3.43%
-3.49%
-30.69%
Total Cash Common Dividend
557.19%
1,152.96%
466.73%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70
37
67
97
271
2025
62
48
- -
38
188
2026
47
89
103
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.03
0.01
0.23
0.27
2025
0.02
0.01
- -
-0.51
-0.48
2026
0.01
0.01
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
- -
0.03
2025
- -
- -
- -
0.11
0.19
2026
- -
- -
- -
- -
- -

Company Description

CEO
Ben Yi Han
Full Time Employees
340
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 138 Huaihai Middle Road Shanghai SH China 200001
IPO Date
May 5, 2015
Business
Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces and sells veterinary biological products primarily for livestock and poultry in China. The company offers a broad portfolio of vaccines including swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; and avian newcastle disease and avian infectious bronchitis combined live vaccines. Founded in 1981 and headquartered in Shanghai, the company operates mainly in the domestic market with a focus on epidemic prevention for major animal diseases and maintains R&D centers recognized as Shanghai Enterprise Technology Center and Shanghai Veterinary Biologics Engineering Technology Research Center. In recent developments, Shanghai Hile Bio-Technology agreed in 2024 to acquire a 55% stake in Shaanxi Reshine Biotech Co., Ltd., a producer of oral tissue repair and regeneration materials, from Maylion Management Limited for approximately CNY 935 million in cash to expand into human biomedical applications amid growing dental implant demand; it also plans to sell its 30% stake in certain vaccine-related assets to WuXi Biologics to streamline operations and enhance liquidity. These strategic moves deepen the company's "human protection" business segment alongside its core "animal insurance" veterinary offerings.